指南与共识类风湿关节炎脊柱关节炎系统性红斑狼疮

2017 ACR/AAHKS 指南:风湿病患者择期全髋或全膝关节置换术围手术期抗风湿药物管理

2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.
指南 / 共识 · Arthritis Rheumatol · 2017-06-16

该指南由美国风湿病学会与美国髋膝关节外科医师协会合作制定,针对类风湿关节炎、脊柱关节炎、幼年特发性关节炎或系统性红斑狼疮成人患者择期全髋或全膝关节置换术,提供围手术期传统改善病情抗风湿药、生物制剂、托法替布和糖皮质激素的继续、停用与重启时机及激素剂量推荐。共7条推荐,均为条件性推荐,基于低或中等质量证据。

要点

  • 涵盖RA、SpA(含AS和PsA)、JIA、SLE成人择期THA或TKA的围手术期抗风湿药管理。
  • 推荐涉及传统DMARDs、生物制剂、托法替布和糖皮质激素的继续、停用与重启时机。
  • 7条推荐均为条件性,基于低或中等质量证据。

核心结论

  • 该指南应有助于临床医生和患者在择期THA或TKA时对抗风湿药物围手术期管理做出决策。
  • 这些条件性推荐反映了缺乏高质量的直接随机对照试验数据。

研究设计与样本

  • 由风湿病学家、髋膝关节置换专科骨科医生和方法学家组成小组构建关键临床问题。
  • 进行多步骤系统文献综述,综合继续与停用抗风湿药及围手术期最佳糖皮质激素管理的证据。
  • 组建患者小组确定患者价值观和偏好,采用GRADE方法通过投票小组共识过程评定证据质量和推荐强度。

主要发现

  • 指南涉及RA、SpA、JIA或SLE成人择期THA或TKA围手术期传统改善病情抗风湿药、生物制剂、托法替布和糖皮质激素的使用。
  • 指南提供关于何时继续、何时停用和何时重启这些药物的推荐,以及围手术期糖皮质激素的最佳剂量。

关键数值与推荐

  • 指南包括7条推荐,均为条件性推荐,基于低或中等质量证据。

临床怎么用

  • 临床医生可参考该指南为RA、SpA、JIA或SLE成人患者择期THA或TKA围手术期抗风湿药物管理提供决策依据。

局限性

  • 推荐为条件性,反映缺乏高质量的直接随机对照试验数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This collaboration between the American College of Rheumatology and the American Association of Hip and Knee Surgeons developed an evidence-based guideline for the perioperative management of antirheumatic drug therapy for adults with rheumatoid arthritis (RA), spondyloarthritis (SpA) including ankylosing spondylitis and psoriatic arthritis, juvenile idiopathic arthritis (JIA), or systemic lupus erythematosus (SLE) undergoing elective total hip (THA) or total knee arthroplasty (TKA). METHODS: A panel of rheumatologists, orthopedic surgeons specializing in hip and knee arthroplasty, and methodologists was convened to construct the key clinical questions to be answered in the guideline. A multi-step systematic literature review was then conducted, from which evidence was synthesized for continuing versus withholding antirheumatic drug therapy and for optimal glucocorticoid management in the perioperative period. A Patient Panel was convened to determine patient values and preferences, and the Grading of Recommendations Assessment, Development and Evaluation methodology was used to rate the quality of evidence and the strength of recommendations, using a group consensus process through a convened Voting Panel of rheumatologists and orthopedic surgeons. The strength of the recommendation reflects the degree of certainty that benefits outweigh harms of the intervention, or vice versa, considering the quality of available evidence and the variability in patient values and preferences. RESULTS: The guideline addresses the perioperative use of antirheumatic drug therapy including traditional disease-modifying antirheumatic drugs, biologic agents, tofacitinib, and glucocorticoids in adults with RA, SpA, JIA, or SLE who are undergoing elective THA or TKA. It provides recommendations regarding when to continue, when to withhold, and when to restart these medications, and the optimal perioperative dosing of glucocorticoids. The guideline includes 7 recommendations, all of which are conditional and based on low- or moderate-quality evidence. CONCLUSION: This guideline should help decision-making by clinicians and patients regarding perioperative antirheumatic medication management at the time of elective THA or TKA. These conditional recommendations reflect the paucity of high-quality direct randomized controlled trial data.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Goodman SM, Springer B, Guyatt G, et al. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. Arthritis Rheumatol. 2017. PMID: 28620948. doi:10.1002/art.40149

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。